Key facts
- This page summarizes Charles A. Deignan's Form 4 filing for Clearside Biomedical, Inc. (CLSD).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 19 Jan 2024, 18:25.
Charles A. Deignan - 18 Jan 2024 Form 4 Insider Report for Clearside Biomedical, Inc. (CLSD)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- CLSD
- Reported as of
- 18 Jan 2024
- Net transaction value
- -$16,512
- SEC form
- 4
- Accepted by SEC
- 19 Jan 2024, 18:25:35 UTC
- Prior SEC filing
- 20 Sep 2023
- Next SEC filing
- 10 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Ballantyne, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Charles A. Deignan filed Form 4 for Clearside Biomedical, Inc. (CLSD) on 19 Jan 2024.
Change
- Previous filing in this sequence was filed on 20 Sep 2023.
- Current net transaction value: -$16,512.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLSD
transaction
Common Stock
Sale
- Transaction value
- $16,512
- Shares
- -12,900
- Change %
- -3.2%
- Price
- $1.28
- Shares after
- 384,662
- Date
- 19 Jan 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLSD
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +200,000
- Change %
- Price
- $0.000000
- Shares after
- 200,000
- Date
- 18 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 200,000
- Exercise price
- $1.29
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.18 to $1.32 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
One-fourth of the shares underlying this option vest on January 18, 2025 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such vesting date.